Switch theme
Sign up to access all valuation multiples
Fresenius SE is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
1912
179.9K+
LTM Revenue $24.7B
LTM EBITDA $4.0B
$39.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fresenius has a last 12-month revenue of $24.7B and a last 12-month EBITDA of $4.0B.
In the most recent fiscal year, Fresenius achieved revenue of $24.6B and an EBITDA of $3.5B.
Fresenius expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fresenius valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $25.1B | $24.6B | XXX | XXX | XXX |
| Gross Profit | $12.1B | $5.7B | XXX | XXX | XXX |
| Gross Margin | 48% | 23% | XXX | XXX | XXX |
| EBITDA | $3.1B | $3.5B | XXX | XXX | XXX |
| EBITDA Margin | 12% | 14% | XXX | XXX | XXX |
| Net Profit | $1.5B | -$668M | XXX | XXX | XXX |
| Net Margin | 6% | -3% | XXX | XXX | XXX |
| Net Debt | $20.9B | $13.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 14, 2025, Fresenius's stock price is EUR 43 (or $48).
Fresenius has current market cap of EUR 24.2B (or $27.2B), and EV of EUR 35.3B (or $39.7B).
See Fresenius trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $39.7B | $27.2B | XXX | XXX | XXX | XXX | $3.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 14, 2025, Fresenius has market cap of $27.2B and EV of $39.7B.
Fresenius's trades at 1.6x LTM EV/Revenue multiple, and 9.9x LTM EBITDA.
Analysts estimate Fresenius's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Fresenius and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $39.7B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 11.2x | XXX | XXX | XXX |
| P/E | 51.3x | XXX | XXX | XXX |
| P/E/Growth | 0.5x | XXX | XXX | XXX |
| EV/FCF | 23.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFresenius's NTM/LTM revenue growth is 5%
Fresenius's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged n/a for the same period.
Over next 12 months, Fresenius's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Fresenius's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Fresenius and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 0% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 0% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fresenius acquired XXX companies to date.
Last acquisition by Fresenius was XXXXXXXX, XXXXX XXXXX XXXXXX . Fresenius acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fresenius founded? | Fresenius was founded in 1912. |
| Where is Fresenius headquartered? | Fresenius is headquartered in Germany. |
| How many employees does Fresenius have? | As of today, Fresenius has 179.9K+ employees. |
| Is Fresenius publicy listed? | Yes, Fresenius is a public company listed on ETR. |
| What is the stock symbol of Fresenius? | Fresenius trades under FRE ticker. |
| When did Fresenius go public? | Fresenius went public in 1992. |
| Who are competitors of Fresenius? | Similar companies to Fresenius include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Fresenius? | Fresenius's current market cap is $27.2B |
| What is the current revenue of Fresenius? | Fresenius's last 12-month revenue is $24.7B. |
| What is the current EBITDA of Fresenius? | Fresenius's last 12-month EBITDA is $4.0B. |
| What is the current EV/Revenue multiple of Fresenius? | Current revenue multiple of Fresenius is 1.6x. |
| What is the current EV/EBITDA multiple of Fresenius? | Current EBITDA multiple of Fresenius is 9.9x. |
| What is the current revenue growth of Fresenius? | Fresenius revenue growth between 2023 and 2024 was -2%. |
| Is Fresenius profitable? | Yes, Fresenius is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
